BioPharmSignal logoBioPharmSignal

Biotech News

Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Arcutis Biotherapeutics (ARQT)Arcutis BiotherapeuticsCompany update

Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitor Atopic dermatitis affects approximately 9.6 million children in the United States WESTLAKE

Related news

ARQTArcutis Biotherapeutics2026-03-10 13:00 EST

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

ARQTArcutis Biotherapeutics2026-03-28 15:00 EST

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

View all latest news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

ARQTArcutis Biotherapeutics2026-08-07 20:00 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-08-05 20:00 EST

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

ARQTArcutis Biotherapeutics2026-07-16 13:00 EST

Arcutis Expands Board of Directors with Appointment of Chris Peetz

ARQTArcutis Biotherapeutics2026-07-15 20:00 EST

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

ARQTArcutis Biotherapeutics2026-07-08 12:00 EST

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Stock data

Close
25.08 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States